Azacitidine and Venetoclax in Previously Untreated Acute ...New England Journal of Medicine
www.nejm.org
von CD DiNardo · · Zitiert von: — DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020;135: Go to Citation. Crossref · PubMed · ISI. von CD DiNardo · · Zitiert von: — DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020;135: Go to Citation. Crossref · PubMed · ISI.
Updated Safety and Efficacy of Venetoclax in Combination ...Genentech
medically.gene.com
von AH Wei · · Zitiert von: 5 — 2018;9(25):17270– Wei AH, et al. Blood ;135(24):2137–45. Scan QR code ... von AH Wei · · Zitiert von: 5 — 2018;9(25):17270– Wei AH, et al. Blood ;135(24):2137–45. Scan QR code ...
Selected Abstracts on Novel Therapies for Hematologic Malignancies -...
www.ascopost.com
Wei AH, Strickland SA, Roboz GJ, et al: Updated safety and efficacy results of phase 1/2 study of venetoclax plus low dose cytarabine in ...
6-month follow-up of VIALE-C demonstrates improved and ...Nature
www.nature.com
von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ... von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ...
Alle Infos zum Namen "Wei Ah"
A Prospective Phase II Study (VALDAC)ASCO Publications
ascopubs.org
von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase
Azacitidine and Venetoclax in Previously Untreated Acute ...Cochrane Library
www.cochranelibrary.com
... Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM ...
Chemotherapy and Venetoclax in Elderly Acute Myeloid ...ASCO Publications
ascopubs.org
von CC Chua · · Zitiert von: 134 — Wei AH, Strickland SA Jr, Hou J-Z, et al: Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia ... von CC Chua · · Zitiert von: 134 — Wei AH, Strickland SA Jr, Hou J-Z, et al: Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia ...
Prof Andrew Wei, Lab Head | WEHI Researcher ProfileWalter and Eliza Hall Institute of Medical Research
www.wehi.edu.au
... Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med 2020;383(7): PMID: Stone RM Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med 2020;383(7): PMID: Stone RM ...
Research publicationsAlfred Health
www.alfredhealth.org.au
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, ... Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, ...
Paper: Acute Myeloid Leukemia Driven IL- ...The Conference Exchange
ash.confex.com
— Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ...
Phase 3 Study Confirms Benefit of Venetoclax/LDAC in ...Targeted Oncology
www.targetedonc.com
— Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase — Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase
AML – Highlights vom EHA-Kongress - Onkologie - Universimed - Medizin...
www.universimed.com
Abstract S1563, EHA 2018, Stockholm 3 Wei AH et al.: Updated safety and efficacy results of phase 1/2 study of venetoclax plus lowdose ...
CAVEAT shows venetoclax plus chemo appropriate for older, fit AML...
www.mdedge.com
Key clinical point: Venetoclax plus attenuated-dose induction chemotherapy may be an option for elderly patients with newly diagnosed AML.Major finding: The...
Venetoclax Granted Breakthrough Therapy Designation by FDA for AML...
www.targetedonc.com
Wei AH, Strickland SA, Roboz GJ, et al. Updated safety and efficacy results of phase 1/2 study of venetoclax plus low-dose cytarabine in ...
Verwandte Suchanfragen zu Wei Ah
|
Personen Vorname "Wei" (618) Name |
sortiert nach Relevanz / Datum